Skip to main content

4 Result(s)

within Valentina Burgio Remove this filter Hematology Remove this filter

and

  1. No Access

    Article

    Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

    The purpose of this study is to compare response rates of lenvatinib and atezolizumab plus bevacizumab, in first-line real-world setting.

    Mara Persano, Margherita Rimini… in Journal of Cancer Research and Clinical On… (2023)

  2. No Access

    Article

    Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients

    The best first-line treatment for patients with advanced hepatocellular carcinoma (HCC) and Child–Pugh (CP) class B remains unknown. The aim of the present study was to perform a real-world analysis on a large...

    Margherita Rimini, Mara Persano… in Journal of Cancer Research and Clinical On… (2023)

  3. No Access

    Article

    Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis

    Recently, three published phase III trials highlighted the superiority of investigational drugs compared to placebo, thus leading to their approval in the second-line setting. We report here a MAIC of second-l...

    Andrea Casadei-Gardini, Lorenza Rimassa… in Journal of Cancer Research and Clinical On… (2021)

  4. No Access

    Article

    Is there any place for novel agents in treating biliary tract cancer?

    Biliary tract cancer is an uncommon cancer in developed countries. In localized stages, surgery is the cornerstone of treatment with curative purpose. Conversely in advanced stages, chemotherapy with platinum–...

    Gianluca Perego, Valentina Burgio, Renata Nozza, Giorgia Longobardo… in Medical Oncology (2021)